Verve Therapeutics Inc (NASDAQ: VERV) flaunted slowness of -2.64% at $5.54, before settling in for the price of $5.69 at the close. Taking a more long-term approach, VERV posted a 52-week range of $4.30-$20.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 126.44%. Meanwhile, its Annual Earning per share during the time was -67.06%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 17.45%. This publicly-traded company’s shares outstanding now amounts to $81.97 million, simultaneously with a float of $62.47 million. The organization now has a market capitalization sitting at $468.79 million.
Verve Therapeutics Inc (VERV) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Verve Therapeutics Inc industry. Verve Therapeutics Inc’s current insider ownership accounts for 26.18%, in contrast to 70.08% institutional ownership. According to the most recent insider trade that took place on May 14 ’24, this organization’s insider bought 76,000 shares at the rate of 6.26, making the entire transaction reach 475,760 in total value, affecting insider ownership by 342,509. Preceding that transaction, on Apr 02 ’24, Company’s Chief Administrative Officer sold 1,514 for 8.24, making the whole transaction’s value amount to 12,475. This particular insider is now the holder of 8,659 in total.
Verve Therapeutics Inc (VERV) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.72 per share during the current fiscal year.
Verve Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 17.45% and is forecasted to reach -2.87 in the upcoming year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Let’s observe the current performance indicators for Verve Therapeutics Inc (VERV). It’s Quick Ratio in the last reported quarter now stands at 14.64. The Stock has managed to achieve an average true range (ATR) of 0.35. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 22.70.
In the same vein, VERV’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.60, a figure that is expected to reach -0.68 in the next quarter, and analysts are predicting that it will be -2.87 at the market close of one year from today.
